Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Context Therapeutics Inc. CNTX
$0.53
-$0.05 (-8.70%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
10031501.00000000
-
week52high
2.52
-
week52low
0.47
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-0.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 04:00
Описание компании
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 02 февр 2022 г. | |
| ThinkEquity | Buy | 24 янв 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lehr Martin A. | A | 143232 | 7027 | 30 янв 2023 г. |
| Lehr Martin A. | A | 136205 | 6839 | 23 янв 2023 г. |
| Lehr Martin A. | A | 129366 | 6783 | 17 янв 2023 г. |
| Minai-Azary Jennifer Lynn | A | 40000 | 25000 | 16 дек 2022 г. |
| Lehr Martin A. | A | 122583 | 20000 | 16 дек 2022 г. |
| Levit Alex C. | A | 9000 | 6000 | 09 дек 2022 г. |
| Lehr Martin A. | A | 102583 | 13000 | 19 авг 2022 г. |
| Minai-Azary Jennifer Lynn | A | 15000 | 15000 | 17 авг 2022 г. |
| Sahmoud Tarek | A | 10000 | 10000 | 16 авг 2022 г. |
| Sahmoud Tarek | A | 25000 | 25000 | 12 авг 2022 г. |
Новостная лента
Context Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancer
Proactive Investors
06 февр 2023 г. в 08:18
Context Therapeutics (NASDAQ:CNTX) Inc has highlighted encouraging clinical responses from its Phase 2 OATH clinical trial evaluating ONA-XR to treat endometrial cancer. The company said that two patients achieved a confirmed partial response among the first 12 patients (9 evaluable) enrolled in the Phase 2 OATH clinical trial evaluating the potential of Context's oral progesterone receptor antagonist onapristone extended release in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer.
7 Top Penny Stocks To Watch With Big News This Week
PennyStocks
31 янв 2023 г. в 09:30
Penny Stocks With News Light Up The Scanners This Week This week
Context Therapeutics says clinical partner Stemline Therapeutics receives FDA approval for ORSERDU to treat certain breast cancers
Proactive Investors
31 янв 2023 г. в 08:33
Context Therapeutics (NASDAQ:CNTX) has announced that its clinical trial collaborator, Stemline Therapeutics Inc, a wholly-owned subsidiary of The Menarini Group, has received approval from the US Food and Drug Administration (FDA) for ORSERDU (elacestrant) for the treatment of postmenopausal women or adult men with estrogen receptor–positive (ER+), HER2-negative (HER2-), Estrogen Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. The Philadelphia-based women's oncology company noted that ORSERDU has shown improved efficacy over the current standard-of-care (SOC) treatment, fulvestrant, in patients with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
Context Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancers
Proactive Investors
09 янв 2023 г. в 09:03
Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, to manufacture Context's clinical development candidate CTIM-76. CTIM-76 is a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody targeting CLDN6 positive tumors, the company noted in a statement.
5 Hot Penny Stocks To Watch This Week With Big News
PennyStocks
09 янв 2023 г. в 09:02
Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.